BDBM142038 US8927577, 117::US8927577, 19::US8927577, 32

SMILES: Cc1cc2ccccc2nc1NC(C1CC(C)(C)C1)c1ccc(cc1)C(=O)NCCC(O)=O

InChI Key: InChIKey=JHYVBNOMIUNRJS-UHFFFAOYSA-N

Data: 3 KI

Find this compound or compounds like it in BindingDB or PDB:

Substructure Similarity at least:  must be >=0.5 Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 3 hits for monomerid = 142038   

Target/Host (Institution)	Ligand	Target/Host Links	Ligand Links	Trg + Lig Links	Ki nM	ΔG° kcal/mole	IC50 nM	Kd nM	EC50/IC50 nM	koff s-1	kon M-1s-1	pH	Temp °C
Glucagon (Homo sapiens (Human))	BDBM142038 (US8927577, 117 | US8927577, 19 | US8927577, 32) Show SMILES Cc1cc2ccccc2nc1NC(C1CC(C)(C)C1)c1ccc(cc1)C(=O)NCCC(O)=O Show InChI InChI=1S/C27H31N3O3/c1-17-14-20-6-4-5-7-22(20)29-25(17)30-24(21-15-27(2,3)16-21)18-8-10-19(11-9-18)26(33)28-13-12-23(31)32/h4-11,14,21,24H,12-13,15-16H2,1-3H3,(H,28,33)(H,29,30)(H,31,32)	Reactome pathway KEGG UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem Similars	US Patent	53	n/a	n/a	n/a	n/a	n/a	n/a	7.4	n/a
Pfizer Inc. US Patent					Assay Description The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptor. Test compoun...				US Patent US8927577 (2015) BindingDB Entry DOI: 10.7270/Q29S1PRV
					More data for this Ligand-Target Pair
Glucagon receptor (Homo sapiens (Human))	BDBM142038 (US8927577, 117 | US8927577, 19 | US8927577, 32) Show SMILES Cc1cc2ccccc2nc1NC(C1CC(C)(C)C1)c1ccc(cc1)C(=O)NCCC(O)=O Show InChI InChI=1S/C27H31N3O3/c1-17-14-20-6-4-5-7-22(20)29-25(17)30-24(21-15-27(2,3)16-21)18-8-10-19(11-9-18)26(33)28-13-12-23(31)32/h4-11,14,21,24H,12-13,15-16H2,1-3H3,(H,28,33)(H,29,30)(H,31,32)	PDB MMDB UniProtKB/SwissProt B.MOAD antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem Similars	PubMed	53	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Pfizer Inc. Curated by ChEMBL					Assay Description Displacement of [125I]-glucagon from human glucagon receptor expressed in Chem-1 cell membranes after 6 to 10 hrs by scintillation proximity assay				Bioorg Med Chem Lett 25: 4057-64 (2015) BindingDB Entry DOI: 10.7270/Q2HM5B7N
					More data for this Ligand-Target Pair
Glucagon (Homo sapiens (Human))	BDBM142038 (US8927577, 117 | US8927577, 19 | US8927577, 32) Show SMILES Cc1cc2ccccc2nc1NC(C1CC(C)(C)C1)c1ccc(cc1)C(=O)NCCC(O)=O Show InChI InChI=1S/C27H31N3O3/c1-17-14-20-6-4-5-7-22(20)29-25(17)30-24(21-15-27(2,3)16-21)18-8-10-19(11-9-18)26(33)28-13-12-23(31)32/h4-11,14,21,24H,12-13,15-16H2,1-3H3,(H,28,33)(H,29,30)(H,31,32)	Reactome pathway KEGG UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem Similars	US Patent	74	n/a	n/a	n/a	n/a	n/a	n/a	7.4	n/a
Pfizer Inc. US Patent					Assay Description The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptor. Test compoun...				US Patent US8927577 (2015) BindingDB Entry DOI: 10.7270/Q29S1PRV
					More data for this Ligand-Target Pair